16-Gene Assay Validated As Outcome Predictor in Clear Cell Renal Cell Carcinoma
the Cancer Therapy Advisor take:
A recurrence score algorithm developed using a 16-gene assay can provide a more accurate and individualized risk assessment beyond existing clinical and pathological parameters in patients with stage I-III clear cell renal cell carcinoma, a new study published online early in the journal The Lancet Oncology has shown.
In order to improve clinical outcome predictions in patients with localized clear cell renal cell carcinoma who have undergone nephrectomy, researchers sought to develop and validate a prognostic multigene signature using molecular characteristics of each patient's tumor.
Researchers selected 16 genes, 11 of which by statistical analyses and five as reference genes. This 16-gene assay was then used to develop a recurrence score algorithm and validated in a cohort of 626 patients with stage I-III clear cell renal cell carcinoma who had undergone nephrectomy.
Results showed that the continuous recurrence score was significantly associated with recurrence-free survival (HR = 3.91 for a 25-unit increase in score; 95% CI: 2.63-5.79; P < 0.0001).
Researchers found that the recurrence score was able to detect a clinically significant number of patients with either high-risk stage I or low-risk stage II-III clear cell renal cell carcinoma.
A recurrence score algorithm using a 16-gene assay can provide a more accurate assessment in stage I-III clear cell RCC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer